Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.535 USD | +0.18% | -35.86% | -17.26% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.26% | 245M | |
+11.24% | 225B | |
+10.68% | 186B | |
+12.85% | 135B | |
+25.67% | 107B | |
+0.91% | 63.56B | |
+6.74% | 51.32B | |
+12.01% | 51.04B | |
+8.27% | 43.3B | |
+4.80% | 36.99B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Upgrades NeuroPace to Equalweight From Underweight, Adjusts Price Target to $6 From $5